Aspirin use improves overall survival in patients with melanoma
Postdiagnosis use of aspirin has been shown to provide a survival advantage in patients with melanoma, a recent study has shown.
An association existed between aspirin use and longer overall survival in univariate analysis and after controlling for age, sex, stage and treatment modalities (hazard ratio [HR], 0.58; 95 percent CI, 0.45–0.75). Aspirin use did not correlate with survival in patients with in situ and stage I melanoma, but it correlated with better survival in stages II (HR, 0.45; 0.24–0.82) and III (HR, 0.57; 0.34–0.96).
There was no statistical significance seen in stage IV patients (HR, 0.55; 0.27–1.13). Furthermore, melanoma was less likely to be diagnosed in stages III or IV among those using aspirin prior to diagnosis.
To determine whether aspirin confers longer survival in patients with melanoma, the authors conducted a retrospective cohort study of 1,522 patients at Indiana University Health who had melanoma diagnosed between 2000 and 2014, and were followed up through September 2016.
“Clinical trials investigating the therapeutic potential of aspirin are warranted,” the authors said, adding that the study was limited by its observational design.
In a previous meta-analysis, results support the therapeutic efficacy of adjuvant interferon alpha for the treatment of patients with high-risk cutaneous melanoma in terms of both disease-free survival and overall survival, to a lower extent. Additionally, interferon is valid as a reference treatment in trials investigating new therapeutic agents for the adjuvant treatment of this population. [Cochrane Database Syst Rev 2013;doi:10.1002/14651858.CD008955.pub2]